Related Experiment Video

Updated: May 21, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Targeted therapy for gastric cancer--current status

Jan Kulig1, Piotr Kołodziejczyk, Piotr Kulig

  • 1Department of General and Gastroenterological Surgery, Jagiellonian University Medical College, Krakow, Poland.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|June 20, 2012
PubMed

Insights

Trastuzumab improves survival for HER2-positive metastatic gastric cancer patients when added to chemotherapy. This targeted therapy offers a significant survival benefit without increasing adverse events, challenging previous treatment limitations.

Area of Science:

  • Oncology
  • Gastroenterology
  • Pharmacology

Background:

  • Metastatic gastric cancer has a poor prognosis with standard chemotherapy.
  • HER2 amplification/over-expression occurs in ~20% of gastric tumors, presenting a target for therapy.
  • Trastuzumab is the first HER2-targeted therapy approved for gastric cancer.

Purpose of the Study:

  • To evaluate the efficacy and safety of adding trastuzumab to chemotherapy in advanced gastric cancer.
  • To assess the impact of HER2-targeted therapy on overall survival in gastric cancer patients.

Main Methods:

  • Clinical trial evaluating trastuzumab plus chemotherapy versus chemotherapy alone.
  • Assessment of overall survival and adverse events.

Main Results:

  • Addition of trastuzumab to chemotherapy significantly improved overall survival.
  • Trastuzumab did not increase the incidence of adverse events compared to chemotherapy alone.

Conclusions:

  • Trastuzumab is an effective and safe addition to chemotherapy for HER2-positive advanced gastric cancer.
  • Targeted therapy targeting HER2 offers a new treatment avenue for gastric cancer.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...